Evercyte Showcases Expertise in Japan’s Pharma Landscape
Evercyte Showcases Expertise in Japan’s Pharma Landscape November 22nd, 2023, Vienna, Austria We recently visited Summit Pharmaceuticals International to present our services
By Giulia Corso|2023-11-22T14:26:44+00:00November 22nd, 2023|cell line development, collaboration, EV cell factories, Extracellular Vesicles, mesenchymal stromal cells|
Evercyte Showcases Expertise in Japan’s Pharma Landscape November 22nd, 2023, Vienna, Austria We recently visited Summit Pharmaceuticals International to present our services
By Giulia Corso|2023-10-27T13:05:07+00:00October 27th, 2023|Extracellular vesicles and ageing, mesenchymal stromal cells|
We participated to the first MOVE symposium in Malaga, Spain October 27th, 2023, Vienna, AustriaWe participated to the first MOVE symposium held
By Giulia Corso|2023-12-01T09:15:19+00:00September 19th, 2023|Extracellular vesicles and ageing, mesenchymal stromal cells|
We participated to the Small New World 2.0 meeting in Graz, Austria September 12th, 2023, Vienna, Austria We participated to the
By Giulia Corso|2023-07-11T09:18:04+00:00May 4th, 2023|EU funded project, Extracellular vesicles and ageing, mesenchymal stromal cells|
We are proud to announce our participation in the CHANGE project May 4th, 2023, Vienna, Austria The CHANGE project focuses on
By Giulia Corso|2023-04-05T11:15:37+00:00April 4th, 2023|Extracellular vesicles, mesenchymal stromal cells|
Recent publication showcasing our telomerized Wharton's jelly-MSCs as EV-cell factories April 4th, 2023, Vienna, AustriaOur telomerized Wharton's jelly-derived MSCs (WJ-MSC/TERT273)
By Evercyte|2021-10-08T08:13:44+00:00September 17th, 2021|Extracellular vesicles|
Engineering of CD81 on extracellular vesicles to target specific cell surface proteins. September 17, 2021, Vienna, AustriaWe have developed a platform technology
By admin|2021-09-17T15:46:31+00:00April 9th, 2021|Extracellular vesicles|
MDimune and Evercyte form partnership for developing tumor-targeting EVs April 1, 2021, Seoul, Korea and Vienna, Austria MDimune Inc. and Evercyte GmbH announced a